Technology
Health
Pharmaceutical

Zymeworks

$14.48
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.28 (-1.86%) Today
-$0.28 (-1.86%) Today

Why Robinhood?

You can buy or sell Zymeworks and other stocks, options, ETFs, and crypto commission-free!

About

Zymeworks Inc., also called Zymeworks, is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. Read More The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani, and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.

Employees
183
Headquarters
Vancouver, British Columbia
Founded
2003
Market Cap
471.67M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
129.60K
High Today
$14.83
Low Today
$14.45
Open Price
$14.75
Volume
7.61K
52 Week High
$29.00
52 Week Low
$10.37

Collections

Technology
Health
Pharmaceutical
Medical
Biopharmaceutical
2017 IPO
Canada
North America

News

Simply Wall StMar 8

Do Directors Own Zymeworks Inc. (TSE:ZYME) Shares?

Every investor in Zymeworks Inc. (TSE:ZYME) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. Companies that have been privatized tend to have low insider ownership. Zymeworks is a smaller company with a market capitalization of CA$690m, so it may still be flying under the radar of many institutional investors. Our analysis of the ownership of the company, below, shows that...

21
MarketBeatMar 7

Stock Price, News, & Analysis for Zymeworks

Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer. It is also developing ZW49, a bispecific antibody-drug conjugate that is in IND application stage. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd....

1
Seeking AlphaMar 6

Zymeworks beats by $0.97

Zymeworks (NYSE:ZYME): Q4 Non-GAAP EPS of $0.33 beats by $0.97 ; GAAP EPS of $0.29 beats by $0.99 . Cash, equivalents and short-term investments of $200.16M (+128.0% Y/Y) Press Release...

43

Earnings

-$0.83
-$0.13
$0.58
$1.28
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected Apr 30, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.